{"organizations": [], "uuid": "0fef1cf1b09ea9e8018124443978d5ca8d6c82c0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180409.html", "section_title": "Archive News &amp; Video for Monday, 09 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-keytruda-monotherapy-met-primary-e/brief-keytruda-monotherapy-met-primary-endpoint-in-phase-3-study-significantly-improving-os-as-first-line-therapy-in-locally-advanced-or-metastatic-nsclc-patients-expressing-pd-l1-in-at-least-1-pct-of-tumor-cells-idUSFWN1RM0JT", "country": "US", "domain_rank": 408, "title": "BRIEF-Keytruda Monotherapy Met Primary Endpoint In Phase 3 Study, Significantly Improving OS As First-Line Therapy In Locally Advanced Or Metastatic NSCLC Patients Expressing PD-L1 In At Least 1 Pct Of Tumor Cells", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.001, "site_type": "news", "published": "2018-04-09T18:56:00.000+03:00", "replies_count": 0, "uuid": "0fef1cf1b09ea9e8018124443978d5ca8d6c82c0"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-keytruda-monotherapy-met-primary-e/brief-keytruda-monotherapy-met-primary-endpoint-in-phase-3-study-significantly-improving-os-as-first-line-therapy-in-locally-advanced-or-metastatic-nsclc-patients-expressing-pd-l1-in-at-least-1-pct-of-tumor-cells-idUSFWN1RM0JT", "ord_in_thread": 0, "title": "BRIEF-Keytruda Monotherapy Met Primary Endpoint In Phase 3 Study, Significantly Improving OS As First-Line Therapy In Locally Advanced Or Metastatic NSCLC Patients Expressing PD-L1 In At Least 1 Pct Of Tumor Cells", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "brief-keytruda monotherapy met primary endpoint", "sentiment": "neutral"}, {"name": "reuters", "sentiment": "neutral"}, {"name": "merck & co inc", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 9 (Reuters) - Merck & Co Inc:\n* KEYTRUDAÂ® (PEMBROLIZUMAB) MONOTHERAPY MET PRIMARY ENDPOINT IN PHASE 3 KEYNOTE-042 STUDY, SIGNIFICANTLY IMPROVING OS AS FIRST-LINE THERAPY IN LOCALLY ADVANCED OR METASTATIC NSCLC PATIENTS EXPRESSING PD-L1 IN AT LEAST 1 PERCENT OF TUMOR CELLS\n* SAFETY PROFILE OF KEYTRUDA IN PHASE 3 TRIAL WAS CONSISTENT\n* PHASE 3 KEYNOTE-042 TRIAL WILL CONTINUE TO EVALUATE PROGRESSION-FREE SURVIVAL (PFS), WHICH IS A SECONDARY ENDPOINT Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-09T18:56:00.000+03:00", "crawled": "2018-04-10T12:53:10.014+03:00", "highlightTitle": ""}